Siegfried Holding Ltd

Research Siegfried Holding Ltd (SFZN) on Bullrun: market cap CHF 3.32B, P/E 19.4, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CHF 3.32B; P/E is 19.4; dividend yield is 0.5%.

Peer valuation comparison

Latest P/E is 19.45x versus a Healthcare sector median of 24.46x (20.5% below).

Latest dividend yield is 0.54% versus a Healthcare sector median of 2.11% (74.4% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CHF 1.33BCHF 168.66M-CHF 3.31M26.7%3.84CHF 103.08Mn/aCHF 1.13B
FY2024CHF 1.29BCHF 160.06M-CHF 12.07M25.4%3.69CHF 38.76Mn/aCHF 980.19M
FY2023CHF 1.27BCHF 112.77MCHF 71.51M25.2%2.62CHF 56.36Mn/aCHF 838.24M
FY2022CHF 1.23BCHF 156.49MCHF 27.13M25.9%3.63CHF 91.48Mn/aCHF 790.93M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CHF 3.32B19.40.5%0.4

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.4 CHF, yield 0.5%.

YearDividends/share
FY20250.38 CHF
FY20240.36 CHF
FY20220.32 CHF
FY20210.3 CHF

About Siegfried Holding Ltd

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Siegfried Holding Ltd's market cap?

Siegfried Holding Ltd's market capitalization is CHF 3.32B.

What is Siegfried Holding Ltd's P/E ratio?

Siegfried Holding Ltd's price-to-earnings (P/E) ratio is 19.4.

Does Siegfried Holding Ltd pay a dividend?

Siegfried Holding Ltd has a dividend yield of 0.5%.

What does Siegfried Holding Ltd do?

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.